Quentin Vicard

Quentin Vicard

MSC & MBA Technology Expert Regenerative Medicine Sartorius Stedim France


Time and date Venue Topic Speakers

Wednesday 20/11/2019

From 15:45 To 16:15

11/20/2019 15:45 11/20/2019 16:15 Suspension adaptation and process development of Multipotent Mesenchymal Stem Cells for cell therapy applications Human mesenchymal stem cells (hMSCs) have great potential as cellular therapeutics due to their ability to differentiate towards multiple lineages. Possible applications range from the treatment of Crohn’s disease to graft versus host disease and also target cardiovascular conditions among others.
To date, the generation of large numbers of hMSCs is typically achieved using two dimensional (2D) tissue culture vessels. However, this culturing approach requires a high level of operator manipulation and offers little in the way of culture control. A possible solution is the scale-up and large-scale production of hMSCs in three dimension (3D) culture on microcarriers utilizing stirred tank bioreactors. Here we demonstrate the utility of the ambr15 and ambr250 modular stirred tank bioreactor systems as valuable tools for hMSC process development and optimization paving the way for the large-scale production of clinically relevant numbers of hMSCs.
Conference Hall L, Hall 7, Pavillion 2

Conference Hall L, Hall 7, Pavillion 2

"Suspension adaptation and process development of Multipotent Mesenchymal Stem Cells for cell therapy applications"

Quentin Vicard
Time and date

Wednesday 20/11/2019

From 15:45 To 16:15

11/20/2019 15:45 11/20/2019 16:15 Suspension adaptation and process development of Multipotent Mesenchymal Stem Cells for cell therapy applications Human mesenchymal stem cells (hMSCs) have great potential as cellular therapeutics due to their ability to differentiate towards multiple lineages. Possible applications range from the treatment of Crohn’s disease to graft versus host disease and also target cardiovascular conditions among others.
To date, the generation of large numbers of hMSCs is typically achieved using two dimensional (2D) tissue culture vessels. However, this culturing approach requires a high level of operator manipulation and offers little in the way of culture control. A possible solution is the scale-up and large-scale production of hMSCs in three dimension (3D) culture on microcarriers utilizing stirred tank bioreactors. Here we demonstrate the utility of the ambr15 and ambr250 modular stirred tank bioreactor systems as valuable tools for hMSC process development and optimization paving the way for the large-scale production of clinically relevant numbers of hMSCs.
Conference Hall L, Hall 7, Pavillion 2
Venue

Conference Hall L, Hall 7, Pavillion 2

Topic
Speakers